Radioisotopes for the palliation of metastatic bone cancer: a systematic review
about
Radioisotopes for metastatic bone painTargeting Bone Metastases in Metastatic Castration-Resistant Prostate CancerComparative efficacy, tolerability, and survival outcomes of various radiopharmaceuticals in castration-resistant prostate cancer with bone metastasis: a meta-analysis of randomized controlled trialsEvolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223Targeting bone physiology for the treatment of metastatic prostate cancerWell-designed bone-seeking radiolabeled compounds for diagnosis and therapy of bone metastasesBiology of bone metastases.Radioisotopes in management of metastatic prostate cancerRadionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate CancerSamarium for osteoblastic bone metastases and osteosarcomaRadium-223 dichloride in clinical practice: a review.Palliative effects and adverse events of strontium-89 for prostate cancer patients with bone metastasis.WITHDRAWN: Radioisotopes for metastatic bone pain.Prostate cancer pain management: EAU guidelines on pain management.In vivo molecular targeted radiotherapy.Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report.Radium-223 for the treatment of castration-resistant prostate cancer.Concurrent use of Sr-89 chloride with zoledronic acid is safe and effective for breast cancer patients with painful bone metastases.First Brazilian Consensus of Advanced Prostate Cancer: Recommendations for Clinical Practice.Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer.Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma.Painful boney metastases.Samarium-153-ethylene diamine tetramethylene phosphonate, a beta-emitting bone-targeted radiopharmaceutical, useful for patients with osteoblastic bone metastasesBone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.May bone-targeted radionuclide therapy overcome PRRT-refractory osseous disease in NET? A pilot report on (188)Re-HEDP treatment in progressive bone metastases after (177)Lu-octreotate.Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival.Effective use of strontium-89 in osseous metastases.The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases.Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases.Radionuclide therapy beyond radioiodine.Radium-223 for the treatment of prostate cancer.Reducing the burden of bone metastases: current concepts and treatment options.Novel bone-targeting agents in prostate cancer.Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies.Metabolism and pharmacokinetics of radium-223 in prostate cancer.Salute to samarium.(223)Ra and other bone-targeting radiopharmaceuticals-the translation of radiation biology into clinical practice.Concurrent use of strontium-89 with external beam radiotherapy for multiple bone metastases: early experience.Harnessing the bone-seeking ability of Ca(II)-like metal ions in the treatment of metastatic cancer and resorption disorders.Comparative Therapeutic Efficacy of 153Sm-EDTMP and 177Lu-EDTMP for Bone Pain Palliation in Patients with Skeletal Metastases: Patients' Pain Score Analysis and Personalized Dosimetry.
P2860
Q24235589-A0E2EF06-A3BA-4479-963C-1CA877042053Q26752785-E3CF3B76-1475-47F8-A3F6-E6D4E6A0FE2BQ26785658-5BE13D27-0417-46B9-BE7E-DD9E4216F2FEQ26861575-C1E59888-E84A-4178-9B86-DC2EBE8FFB62Q26863249-5EC5E73A-7D62-4EA1-AA47-67C49D556301Q27002591-FC4E7354-4D93-4C2B-9EB9-EA8E2F724506Q27693653-D4F72C07-F7BB-4A8F-8BA7-2FF44FE09BB8Q28068134-FB9E019F-708D-4F6E-A18D-D31512032F67Q28079918-753092AF-5F63-474B-B122-30B53AC23792Q28253337-4811024B-6DA8-4F40-A5DA-72825B7975D4Q30251496-28FBE04E-B038-4DA5-81BC-F4619B8EB575Q33419135-5D0706AA-8FD4-4BC3-BD0B-CE2FFEBC47D0Q33440341-C296E341-555B-4493-A4EE-5725C3F927D5Q34154173-24D534FE-F2FC-4A74-B460-CAF1E45911FBQ34991297-7498E76D-0B3E-4820-95C1-DFCF1753295CQ35623683-7C2B8D52-AF82-4236-8A3F-1B70C4C68419Q35653986-DE4ADF73-476B-4AA8-B9C8-E673A0D1E869Q36224128-CBA117EF-24E8-4FDB-A477-7B8E2C922453Q36280995-CE8CAA3C-9C43-4649-93AB-C3B0A77E476CQ36840731-BD6AF6DB-7A40-4019-8A48-00253E54D09DQ37004657-87C80E8A-1E5D-4CC7-963C-D7B8A790110AQ37011060-CA8EB8D7-EDE1-467D-9FB0-9395A5DF915BQ37103630-13412D38-9A6F-4A7B-BCD8-84295040439BQ37166534-AB63797F-2EE7-4F63-90C3-DED3F820E84AQ37402627-B00C071B-134C-41F4-9164-C402E9F23982Q37662701-662E68A3-8DF0-4F05-857D-5A5E76B473B0Q37967436-4F3B28B8-2A35-4360-8683-0725741654E7Q38001275-DCC42EEA-5288-4EB0-8A27-6CC96008E609Q38004275-72DCDA5C-CF1E-40A7-9E90-DE985467EFE3Q38027798-9095D10D-F7E9-4A9B-8829-978FCB8C7BF7Q38073823-D2A813FC-8BD4-47C3-A8F3-2A9955C64FBFQ38087306-89A6CBDE-7595-4DD4-9855-14F9255A6876Q38198934-881C6AE8-346F-45DE-9380-6E43AC089FF2Q38244522-DFF151B5-4AAE-4BB8-8E03-95EE2BE59714Q38367715-36CCDE3D-F0DF-401F-A7DE-0B8D445B462CQ38378076-EE6C13EB-327D-4F57-9ECF-F72BE73E9D7AQ38391693-D84F9F1A-AD7A-4CEA-9A0B-E2618953260CQ38565304-FD174CCA-361A-449D-B253-DDDE38AE55CCQ38725565-3FD13A73-F373-4542-BEFD-07E2A383466AQ38784378-5F6B47AE-DF55-4637-B2D0-980333BE1A43
P2860
Radioisotopes for the palliation of metastatic bone cancer: a systematic review
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Radioisotopes for the palliation of metastatic bone cancer: a systematic review
@ast
Radioisotopes for the palliation of metastatic bone cancer: a systematic review
@en
Radioisotopes for the palliation of metastatic bone cancer: a systematic review
@nl
type
label
Radioisotopes for the palliation of metastatic bone cancer: a systematic review
@ast
Radioisotopes for the palliation of metastatic bone cancer: a systematic review
@en
Radioisotopes for the palliation of metastatic bone cancer: a systematic review
@nl
prefLabel
Radioisotopes for the palliation of metastatic bone cancer: a systematic review
@ast
Radioisotopes for the palliation of metastatic bone cancer: a systematic review
@en
Radioisotopes for the palliation of metastatic bone cancer: a systematic review
@nl
P2093
P3181
P1433
P1476
Radioisotopes for the palliation of metastatic bone cancer: a systematic review
@en
P2093
Ilora G Finlay
Malcolm D Mason
Mike Shelley
P304
P3181
P356
10.1016/S1470-2045(05)70206-0
P407
P577
2005-06-01T00:00:00Z